779 related articles for article (PubMed ID: 10989702)
1. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
Friedrich F
Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
[TBL] [Abstract][Full Text] [Related]
2. Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans.
Friedrich F
Acta Virol; 1998 Jun; 42(3):187-94. PubMed ID: 9842449
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-associated paralytic poliomyelitis and other diseases with acute flaccid paralysis syndrome in Belarus.
Samoilovich EO; Feldman EV; Yermalovich MA; Protas II; Titov LP
Cent Eur J Public Health; 2003 Dec; 11(4):213-8. PubMed ID: 14768785
[TBL] [Abstract][Full Text] [Related]
4. [Intense campaign for vaccination with the oral polio vaccine: what are the repercussions on the enterovirus world?].
Delpeyroux F; Guillot S; Szendröi A; Balanant J; Caro V; Cuervo N; Chevaliez S; Dahourou G; Crainic R
Bull Soc Pathol Exot; 2000 Jul; 93(3):193-7. PubMed ID: 11030056
[TBL] [Abstract][Full Text] [Related]
5. A developing country perspective on vaccine-associated paralytic poliomyelitis.
John TJ
Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
[TBL] [Abstract][Full Text] [Related]
6. Strengths and weaknesses of current polio vaccines--a view from industry.
André FE
Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
[TBL] [Abstract][Full Text] [Related]
7. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
[TBL] [Abstract][Full Text] [Related]
8. Update on vaccine-derived polioviruses.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(40):1093-7. PubMed ID: 17035927
[TBL] [Abstract][Full Text] [Related]
9. [End phase challenges of poliomyelitis eradication programme realization].
Jarzabek Z
Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
[TBL] [Abstract][Full Text] [Related]
10. Polio eradication: the OPV paradox.
Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
[TBL] [Abstract][Full Text] [Related]
11. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
[TBL] [Abstract][Full Text] [Related]
12. Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Jul; 46(28):641-3. PubMed ID: 9233551
[TBL] [Abstract][Full Text] [Related]
13. [Circulation of the poliovirus in endemic zones with children vaccinated by the oral polio vaccine].
Gouandjika I; Rakoto Andrianarivelo M; Akoua-Koffi C; Zeller H; Ehouman A; Morvan JM
Bull Soc Pathol Exot; 2000 Jul; 93(3):198-201. PubMed ID: 11030057
[TBL] [Abstract][Full Text] [Related]
14. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
15. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees.
Friedrich F
Acta Virol; 1996 Jun; 40(3):157-70. PubMed ID: 8891097
[TBL] [Abstract][Full Text] [Related]
16. Vaccine-derived polioviruses and the endgame strategy for global polio eradication.
Kew OM; Sutter RW; de Gourville EM; Dowdle WR; Pallansch MA
Annu Rev Microbiol; 2005; 59():587-635. PubMed ID: 16153180
[TBL] [Abstract][Full Text] [Related]
17. Use of mutational pattern in 5'-NCR and VP1 regions of polioviruses for molecular diagnosis.
Pliaka V; Dedepsidis E; Kyriakopoulou Z; Papadopoulou I; Levidiotou S; Markoulatos P
Mol Cell Probes; 2007 Aug; 21(4):267-75. PubMed ID: 17336496
[TBL] [Abstract][Full Text] [Related]
18. A vision of a world without polio: the OPV cessation strategy.
Heymann DL; Sutter RW; Aylward RB
Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.
Minor P
Vaccine; 2009 May; 27(20):2649-52. PubMed ID: 19428874
[TBL] [Abstract][Full Text] [Related]
20. Laboratory surveillance for wild and vaccine-derived polioviruses--worldwide, January 2007-June 2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Sep; 57(35):967-70. PubMed ID: 18772852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
